相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Minimal Residual Disease in Multiple Myeloma
Nikhil C. Munshi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials
Bruno Paiva et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Bruno Paiva et al.
BLOOD (2012)
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Laura Rosinol et al.
BLOOD (2012)
EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations
A. W. Langerak et al.
LEUKEMIA (2012)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Long-term prognostic significance of response in multiple myeloma after stem cell transplantation
Joaquin Martinez-Lopez et al.
BLOOD (2011)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
Bruno Paiva et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Immunophenotyping in multiple myeloma and related plasma cell disorders
Shaji Kumar et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
Marco Ladetto et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Maria-Victoria Mateos et al.
LANCET ONCOLOGY (2010)
The role of complete response in multiple myeloma
Jean-Luc Harousseau et al.
BLOOD (2009)
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
Cheng E. Chee et al.
BLOOD (2009)
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
Bruno Paiva et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva et al.
BLOOD (2008)
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction:: the prognostic impact of achieving molecular response
Pilar Martinez-Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
Juan Jose Lahuerta et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
Helgi J. K. van de Velde et al.
HAEMATOLOGICA (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
S Galimberti et al.
LEUKEMIA RESEARCH (2005)
Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma
MS Raab et al.
ANNALS OF ONCOLOGY (2005)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
JJM van Dongen et al.
LEUKEMIA (2003)
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR
VHJ van der Velden et al.
LEUKEMIA (2002)
Minimal residual disease monitoring in multiple myeloma
FE Davies et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2002)
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma
FE Davies et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients
JJ Lahuerta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
